Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;46(1):129-138.
doi: 10.1007/s00259-018-4167-0. Epub 2018 Sep 19.

225 Ac-PSMA-617 in Chemotherapy-Naive Patients With Advanced Prostate Cancer: A Pilot Study

Affiliations
Free PMC article

225 Ac-PSMA-617 in Chemotherapy-Naive Patients With Advanced Prostate Cancer: A Pilot Study

Mike Sathekge et al. Eur J Nucl Med Mol Imaging. .
Free PMC article

Erratum in

Abstract

Background: A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. We report our experience with 225Ac-PSMA-617 therapy in chemotherapy-naïve patients with advanced metastatic prostate carcinoma.

Methods: Seventeen patients with advanced prostate cancer were selected for treatment with 225Ac-PSMA-617 in 2-month intervals, with initial activity of 8 MBq, then de-escalation to 7 MBq, 6 MBq or 4 MBq in cases of good response. In one patient, activity was escalated to 13 MBq in the third cycle. Fourteen patients had three treatment cycles administered, while in three patients treatment was discontinued after two cycles due to good response. Six out of 17 patients received additional treatments after the third cycle. Prostate-specific antigen (PSA) was measured every 4 weeks for PSA response assessment. 68Ga-PSMA-PET/CT was used for functional response assessment before each subsequent treatment cycle. Serial full blood count, renal function test, and liver function were obtained to determine treatment-related side effects.

Results: Good antitumor activity assessed by serum PSA level and 68Ga-PSMA-PET/CT was seen in 16/17 patients. In 14/17 patients, PSA decline ≥90% was seen after treatment, including seven patients with undetectable serum PSA following two (2/7) or three cycles (5/7) cycles of 225Ac-PSMA-617. Fifteen of 17 patients had a > 50% decline in lesions avidity for tracer on 68Ga-PSMA-PET/CT including 11 patients with complete resolution (PET-negative and either stable sclerosis on CT for bone or resolution of lymph node metastases) of all metastatic lesions. Grade 1/2 xerostomia was seen in all patients, and none was severe enough to lead to discontinuation of treatment. One patient had with extensive bone marrow metastases and a background anemia developed a grade 3 anemia while another patient with solitary kidney and pre-treatment grade 3 renal failure developed grade 4 renal toxicity following treatment. The group presented with significant palliation of bone pain and reduced toxicity to salivary glands due to de-escalation.

Conclusions: 225Ac-PSMA-617 RLT of chemotherapy-naïve patients with advanced metastatic prostate carcinoma led to a ≥ 90% decline in serum PSA in 82% of patients including 41% of patients with undetectable serum PSA who remained in remission 12 months after therapy. The remarkable therapeutic efficacy reported in this study could be achieved with reduced toxicity to salivary glands due to de-escalation of administered activities in subsequent treatment cycles. This necessitates further exploration for informing clinical practice and clinical trial design.

Keywords: Actinium-225; Chemotherapy-naïve; PSA response; PSMA; Prostate cancer; Radioligand therapy.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
a Waterfall plot showing PSA response at 8 weeks after one cycle of 225Ac-PSMA-617 radioligand therapy. b Waterfall plot showing best PSA response to 225Ac-PSMA-617 radioligand therapy
Fig. 2
Fig. 2
A patient with progressive disease while on androgen deprivation therapy achieved a complete response after three cycles of 225Ac-PSMA-617 (patient number 10, Table 1). He remained symptom-free on 11-month follow-up with his serum PSA remaining below detectable level and the follow-up 68Ga-PSMA-11 PET/CT scan remaining negative for disease recurrence
Fig. 3
Fig. 3
A treatment-naïve patient who presented with extensive bone metastasis at primary diagnosis achieved a complete remission after three cycles of 225Ac-PSMA-617 with de-escalating activities of 8/7/6 MBq (patient number 16, Table 1). He also remained symptom-free on 11-month follow-up with his serum PSA remaining below detectable level and the follow-up 68Ga-PSMA-11 PET/CT scan remaining negative for disease recurrence
Fig. 4
Fig. 4
An example of a patient with progressive disease under therapy with 225Ac-PSMA-617 after pre-treatment with prostatectomy, external beam radiation and androgen deprivation therapy. The patient decided to switch to chemotherapy and died 4 months after the last cycle of 225Ac-PSMA-617 (patient number 1, Table 1)
Fig. 5
Fig. 5
Bar charts comparing results of leucocyte count and hemoglobin (A), as well as serum creatinine and albumin (B) obtained at baseline and at the completion of 225Ac-PSMA-617 PRLT. The differences in the pre-treatment and follow-up measurements of leucocyte count (p = 0.292), hemoglobin level (p = 0.485), serum creatinine level (p = 0.683) and serum albumin level (p = 0.633) did not reach statistical significance

Comment in

Similar articles

See all similar articles

Cited by 25 articles

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–1092. doi: 10.1016/j.eururo.2012.02.054. - DOI - PubMed
    1. Kgatle MM, Kalla AA, Islam MM, Sathekge M, Moorad R. Prostate cancer: epigenetic alterations, risk factors, and therapy. Prostate Cancer. 2016;2016:5653862. doi: 10.1155/2016/5653862. - DOI - PMC - PubMed
    1. Sathekge M, Lengana T, Maes A, Vorster M, Zeevaart J, Lawal I, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white south-Africans. Eur J Nucl Med Mol Imaging. 2018;45(2):226–234. doi: 10.1007/s00259-017-3852-8. - DOI - PMC - PubMed
    1. Lengana T, van de Wiele C, Lawal I, Maes A, Ebenhan T, Boshomane T, et al. 68Ga-PSMA-HBED-CC PET/CT imaging in black versus white south African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study. Nucl Med Commun. 2018;39(2):179–185. - PubMed

MeSH terms

Feedback